Free Submission Public Relations &
Deutsch English


New Market Report: Peritoneal Cancer - Pipeline Review, H1 2013

Print article Print article
2013-04-05 02:49:27 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. Peritoneal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- ..

Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.


* A snapshot of the global therapeutic scenario for Peritoneal Cancer.
* A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Peritoneal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Peritoneal Cancer
Peritoneal Cancer Therapeutics under Development by Companies
Peritoneal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Peritoneal Cancer Therapeutics - Products under Development by Companies
Peritoneal Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Peritoneal Cancer Therapeutics Development
Boehringer Ingelheim GmbH
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Oxford BioMedica plc
Millennium Pharmaceuticals, Inc.
Novartis AG
Cell Therapeutics, Inc.
Bayer AG
EntreMed, Inc.
Marshall Edwards, Inc.
Oncolytics Biotech Inc.
Array BioPharma Inc.
Synta Pharmaceuticals Corp.
Spectrum Pharmaceuticals, Inc.
Fresenius Biotech GmbH
CritiTech, Inc.
Viral Genetics, Inc.
ImmunoVaccine Technologies Inc.
Genelux Corporation
TRACON Pharmaceuticals, Inc.
RECEPTA Biopharma S.A.
Kyowa Hakko Kirin Pharma, Inc.
Peritoneal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
trebananib - Drug Profile
enzastaurin hydrochloride - Drug Profile
sorafenib tosylate - Drug Profile
alisertib - Drug Profile
paclitaxel poliglumex - Drug Profile
selumetinib sulfate - Drug Profile
ENMD-2076 - Drug Profile
elesclomol - Drug Profile
TroVax - Drug Profile
ramucirumab - Drug Profile
MEK-162 - Drug Profile
vatalanib + [docetaxel] - Drug Profile
erlotinib hydrochloride + [bevacizumab] + [carboplatin] + [paclitaxel] - Drug Profile
bendamustine hydrochloride - Drug Profile
idronoxil + [carboplatin] - Drug Profile
Docetaxel + Yondelis + Pegfilgrastim - Drug Profile
docetaxel + [trabectedin] + pegfilgrastim - Drug Profile
Docetaxel + Carboplatin + Pegfilgrastim - Drug Profile
ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine + [sargramostim] - Drug Profile
trebananib + [doxorubicin liposomal] - Drug Profile
Taxotere + Eloxatin + Avastin - Drug Profile
TRC-105 - Drug Profile
Monoclonal antibody hu3S193 - Anti-LeY - Drug Profile
GL-ONC-1 - Drug Profile
pemetrexed disodium + [carboplatin] - Drug Profile
pemetrexed disodium + [bevacizumab] - Drug Profile
erlotinib hydrochloride + [bevacizumab] - Drug Profile
paclitaxel - Drug Profile
paclitaxel albumin-bound + [bevacizumab] - Drug Profile
EGEN-001 - Drug Profile
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile
everolimus + [bevacizumab] - Drug Profile
OCDC Dendritic Cell Vaccine - Drug Profile
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile
bevacizumab + [irinotecan hydrochloride] - Drug Profile
Reolysin + [paclitaxel] - Drug Profile
NY-ESO-1 Overlapping Peptides Vaccine - Drug Profile

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact